Is gene discovery research or diagnosis?

Genetics in Medicine

Volumn 10, Issue 6, 2008, Pages 385-390

  Samuels, Mark E ^a,f   Orr, Andrew ^b   Guernsey, Duane L ^c   Dooley, Kent ^d   Riddell, Christie ^d   Hodgkinson, Kathy ^e   Ludman, Mark ^d   Pullman, Daryl ^e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Department of Ophthalmology and Visual Sciences ^*

^c DALHOUSIE UNIVERSITY   (Canada)

^d IWK HEALTH CENTRE   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Gene discovery; Genetics ethics; Genetics research; Molecular diagnostics; Whole genome resequencing

Indexed keywords

DNA;

ALLELE; CHROMOSOME ANALYSIS; CLINICAL MEDICINE; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MEDICAL PRACTICE; MOLECULAR GENETICS; PHENOTYPE; REVIEW; ARTICLE; CANADA; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; GENETIC PROCEDURES; GENETICS; GENOME; MEDICAL RESEARCH; RESEARCH ETHICS; SCIENCE; UNITED STATES;

BIOMEDICAL RESEARCH; CANADA; CLINICAL MEDICINE; DRUG INDUSTRY; ETHICS, RESEARCH; GENETIC RESEARCH; GENETIC TECHNIQUES; GENETICS; GENOME; HUMANS; RESEARCH SUPPORT AS TOPIC; SCIENCE; SEQUENCE ANALYSIS, DNA; UNITED STATES;

EID: 48849099595     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181770172     Document Type: Review

References (62)

1. Tri-Council. Ethical conduct for research involving humans. Canada: Public Works and Government Services, 2003.
2. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, 1964.
3. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. US Department of Health Education, and Welfare, 1979.
4. Bevan JC, Hardy JF. Permission to publish case reports/case series. Can J Anaesth 2004;51:861-866.
5. Shevell M. The ethics of case reports. Paediatr Child Health 2004;9:83-84.
6. Pullman D, Hodgkinson K. Genetic knowledge and moral responsibility: ambiguity at the interface of genetic research and clinical practice. Clin Genet 2006;69:199-203.
7. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 2004;41:492-507.
8. Phelan CM, Dapic V, Tice B, Favis R, et al. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 2005;42:138-146.
9. Piovani G, Borsani G, Bertini V, Kalscheuer VM, et al. Unexpected identification of two interstitial deletions in a patient with a pericentric inversion of a chromosome 4 and an abnormal phenotype. Eur J Med Genet 2006;49:215-223.
10. Spruijt L, Engelen JJ, Bruinen-Smeijsters IP, Albrechts JC, et al. A patient with a de novo 15q24q26.1 interstitial deletion, developmental delay, mild dysmorphism, and very blue irises. Am J Med Genet A 2004;129:312-315.
11. Pinson L, Perrin A, Plouzennec C, Parent P, et al. Detection of an unexpected subtelomeric 15q26.2 3qter deletion in a little girl: clinical and cytogenetic studies. Am J Med Genet A 2005;138:160-165.
12. Baynam G, Goldblatt J, Townshend S. A case of 3q29 microdeletion with novel features and a review of cytogenetically visible terminal 3q deletions. Clin Dysmor-phol 2006;15:145-148.
13. Rauch A, Hoyer J, Guth S, Zweier C, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006;140:2063-2074.
14. Tajsharghi H, Ohlsson M, Lindberg C, Oldfors A. Congenital myopathy with nema-line rods and cap structures caused by a mutation in the beta-tropomyosin gene (TPM2). Arch Neurol 2007;64:1334-1338.
15. Al-Dirbashi OY, Abu-Amero KK, Alswaid AF, Hoffmann GF, et al. LC-MS/MS determination of dibasic amino acids for the diagnosis of cystinuria. Application in a family affected by a novel splice-acceptor site mutation in the SLC7A9 gene. J Inherit Metab Dis 2007;30:611.
16. Shrimpton AE, Schelper RL, Linke RP, Hardy J, et al. A presenilin 1 mutation (L420R) in a family with early onset Alzheimer disease, seizures and cotton wool plaques, but not spastic paraparesis. Neuropathology 2007;27:228-232.
17. Rosello M, Monfort S, Orellana C, Oltra S, et al. [Subtelomeric deletion 9qter: definition of the syndrome and parental origin in 2 patients]. Med Clin (Barc) 2007;128:419-421.
18. Wajid M, Bazzi H, Rockey J, Lubetkin J, et al. Localized autosomal recessive hypotricho-sis due to a frameshift mutation in the desmoglein 4 gene exhibits extensive phenotypic variability within a Pakistani family. J Invest Dermatol 2007;127:1779-1782.
19. Parker M, Ashcroft R, Wilkie AO, Kent A. Ethical review of research into rare genetic disorders. BMJ 2004;31 329:288-289.
20. Sheffield VC, Stone EM, Carmi R. Use of isolated inbred human populations for identification of disease genes. Trends Genet 1998;14:391-396.
21. Laberge AM, Michaud J, Richter A, Lemyre E, et al. Population history and its impact on medical genetics in Quebec. Clin Genet 2005;68:287-301.
22. Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Genet 1999;8:1913-1923.
23. Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 2005;45:400-408.
24. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004;65:419-422.
25. Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004;114:349-353.
26. Zhang LL, Lin ZM, Ma ZH, Xu Z, et al. Mutation hotspots of SCN9A in primary erythermalgia. Br J Dermatol 2007;156:767-769.
27. Samuels ME, Dube MP. Linkage mapping. In: Encyclopedia of genetics, genomics, proteomics, and bioinformatics, part 2, Genetics, Canada: John Wiley & Sons, 2005.
28. Samuels M, Higgins B, Provost S, Marcadier J, et al. New technologies in human genetic analysis. Am Biotechnol Lab 2007;25:22-27.
29. Matsuzaki H, Loi H, Dong S, Tsai YY, et al. Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res 2004; 14:414-425.
30. Sellick GS, Longman C, Tolmie J, Newbury-Ecob R, et al. Genomewide linkage searches for Mendelian disease loci can be efficiently conducted using high-density SNP genotyping arrays. Nucl Acids Res 2004;32:e164.
31. Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006;15 Spec No 1:R57-R66.
32. Redon R, Ishikawa S, Fitch KR, Feuk L, et al. Global variation in copy number in the human genome. Nature 2006;444:444-454. (Pubitemid 44809057)
33. Friedman JM, Baross A, Delaney AD, Ally A, et al. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. Am J Hum Genet 2006;79:500-513.
34. Aradhya S, Cherry AM. Array-based comparative genomic hybridization: clinical contexts for targeted and whole-genome designs. Genet Med 2007;9:553-559.
35. Manning M, Hudgins L. Use of array-based technology in the practice of medical genetics. Genet Med 2007;9:650-653.
36. Clamp M, Fry B, Kamal M, Xie X, et al. Distinguishing protein-coding and noncod-ing genes in the human genome. Proc Natl Acad Sci USA 2007;104:19428-19433.
37. Antonarakis SE, Beckmann JS. Mendelian disorders deserve more attention. Nat Rev Genet 2006;7:277-282.
38. The International HapMap Project. Nature 2003;426:789-796.
39. Ropers HH. New perspectives for the elucidation of genetic disorders. Am J Hum Genet 2007;81:199-207.
40. Tabor HK, Cho MK. Ethical implications of array comparative genomic hybridization in complex phenotypes: points to consider in research. Genet Med 2007;9:626-631.
41. Kimmelman J. The post-human genome project mindset: race, reliability, and health care. Clin Genet 2006;70:427-432.
42. Kerem E, Rave-Harel N, Augarten A, Madgar I, et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997;155:1914-1920.
43. Mussaffi H, Prais D, Mei-Zahav M, Blau H. Cystic fibrosis mutations with widely variable phenotype: the D1152H example. Pediatr Pulmonol 2006;41:250-254.
44. Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketo-nuria. Trends Genet 1999;15:267-272.
45. Watson MS, Mann MY, Lloyd-Puryear M, Rinaldo P, et al. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 2006;117(5 pt 2):S296-S307.
46. Feuchtbaum L, Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 2006;117(5 pt 2):S280-S286.
47. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002;110:781-786.
48. Noorani HZ, Khan HN, Gallie BL, Detsky AS. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 1996;59:301-307.
49. Joseph B, Shanmugam MP, Srinivasan MK, Kumaramanickavel G. Retinoblastoma: genetic testing versus conventional clinical screening in India. Mol Diagn 2004;8: 237-243.
50. Levy S, Sutton G, Ng PC, Feuk L, et al. The diploid genome sequence of an individual human. PLoS Biol 2007;5:e2000000000054.
51. Wheeler DA, Srinivasan M, Egholm M, Shen Y, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008;452:872-876.
52. Bentley D. The impact of new DNA sequencing technologies on human genetics. HUGO HGM2007. Montreal, 2007.
53. Bentley DR. Whole-genome re-sequencing. Curr Opin Genet Dev 2006;16:545-552.
54. Mardis ER. Anticipating the 1,000 dollar genome. Genome Biol 2006;7:112.
55. Robertson JA. The $1000 genome: ethical and legal issues in whole genome sequencing of individuals. Am J Bioeth 2003;3:W-IF1.
56. McGuire AL, Caulfield T, Cho MK. Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet 2008;9:152-156.
57. Glasziou P, Chalmers I. Ethics review roulette: what can we learn? BMJ 2004;328: 121-122.
58. Lewis JC, Tomkins S, Sampson JR. Ethical approval for research involving geographically dispersed subjects: unsuitability of the UK MREC/LREC system and relevance to uncommon genetic disorders. J Med Ethics 2001;27:347-351.
59. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood) 2004;Suppl Web Exclusives: W4-284-296.
60. Wexler A. Mapping fate. Crown, 1995.
61. Pagon RA. Gene tests: an online genetic information resource for health care providers. J Med Libr Assoc 2006;94:343-348.
62. Emery AE, Elliott D, Moores M, Smith C. A genetic register system (RAPID). J Med Genet 1974;11:145-151.